Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Phase IIb, Open-Label, Dose Ranging Study of 13-Valent Pneumococcal Conjugate Vaccine in Adults 55 Through 74 Years of Age Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine

This study has been completed.
Information provided by (Responsible Party):
National Institute of Allergy and Infectious Diseases (NIAID) Identifier:
First received: July 19, 2012
Last updated: April 7, 2016
Last verified: July 2015
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: February 2016
  Primary Completion Date: August 2015 (Final data collection date for primary outcome measure)